If this box remains here for more than 30 seconds, click this link to try again.
Products & Services »
Best Practice Database
Medical Affairs » Patient Advocacy
Download FREE Excerpt
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
Esteemed for their dedication to improving health and providing access to relevant information, patient advocacy groups are uniquely positioned to inform and educate consumers. This benchmarking study identifies effective communication practices for bio-pharmaceutical organizations seeking to better collaborate and manage relationships with key patient advocacy groups. In addition, this study explores different organizational structures for pharma advocacy groups, as well as critical competencies for advocacy liaisons.
Best Practices, LLC designed this benchmarking study to help companies identify key benchmark metrics, executive insights and recommendations that can be used to increase effectiveness when working with patient advocacy groups. In addition it also uncovers current trends, lessons learned and pitfalls to avoid while collaborating with patient advocacy groups.
Develop an expertise structure to support rapid response to external special interest groups – both positive and negative – to allow immediate resolution of issues and support intelligence gathering. Create a communications infrastructure for rapid response. Deputize communications leaders for hostile interactions, and centralize information management and response protocols. Stay informed through rapid global updates on hostile group activities.
Respond locally to attacks to avoid global issue spread. Never antagonize groups whose interests diverge from yours
Insights are drawn from survey responses from a total of 58 research participants at 43 pharmaceutical, biotechnology, and medical device companies. More than a dozen in-depth interviews were conducted to gather more detailed information pertinent to this study. Approximately half of the benchmark class (28 participants) consisted of executives representing top 50 bio-pharmaceutical companies.